Company intelligence / Profile preview

Maestro Therapeutics

United States

Ownership: Private
Development stage: Preclinical

Overview

Maestro Therapeutics operates as an emerging R&D and consulting/advisory enterprise dedicated to transforming and accelerating peptide modality therapeutics. The company engages with academia, biotech, pharma, investors, contract organizations, and vendors to advance preclinical research and clinical development in the peptide space. It does not have its own drug pipeline or published clinical results but leverages deep industry experience for client projects.

Therapeutic areas: OncologyDermatologyCardiovascular
Modalities: PeptidesPeptidomimeticsSmall molecule (consulting expertise)Natural product drug discovery (consulting expertise)
Industry: Consulting

Partnerships

Engages with academia, biotech/pharma companies globally through project-based collaborations. No major publicized corporate partnerships.

Beyond the preview

Go deeper on Maestro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maestro Therapeutics.

Explore the full profile